Regeneron Pharmaceuticals (MEX:REGN) Scaled Net Operating Assets : 0.66 (As of Sep. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Regeneron Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Regeneron Pharmaceuticals's operating assets for the quarter that ended in Sep. 2024 was MXN544,346 Mil. Regeneron Pharmaceuticals's operating liabilities for the quarter that ended in Sep. 2024 was MXN106,564 Mil. Regeneron Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2024 was MXN661,114 Mil. Therefore, Regeneron Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.66.

Regeneron Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Regeneron Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Scaled Net Operating Assets Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.70

0.72

0.95

0.69

0.53

Regeneron Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.59	0.54	0.57	0.68	0.66

Competitive Comparison of Regeneron Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regeneron Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Scaled Net Operating Assets falls into.

Regeneron Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Regeneron Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(377429.193	-	74757.983)	/	569565.892
=	0.53

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	561511.518	-	184082.325
=	377429.193

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	120637.678	-	45879.695	-	0
=	74757.983

Regeneron Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2024 )
=	(Operating Assets (Q: Sep. 2024 )	-	Operating Liabilities (Q: Sep. 2024 ))	/	Total Assets (Q: Jun. 2024 )
=	(544346.22	-	106563.904)	/	661113.894
=	0.66

where

	Operating Assets		(Q: Sep. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	737242.244	-	192896.024
=	544346.22

	Operating Liabilities		(Q: Sep. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	159806.475	-	53242.571	-	0
=	106563.904

Regeneron Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (MEX:REGN) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

REGN:USA 1REGN:Italy 0R2M:UK RGO:Germany RGO:Germany REGN34:Brazil REGN:Austria

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).